The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
801
September 22, 1989
View Complete Issue         Table of Contents 2019 
Low Osmolality Contrast Agents
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Low Osmolality Contrast Agents
September 22, 1989 (Issue: 801)
The US Food and Drug Administration recently approved the marketing of ioversol (Optiray - Mallinckrodt), a new iodinated, low-osmolality, non-ionic X-ray contrast agent. Low-osmolality contrast agents are much more expensive, but they provide as ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Low Osmolality Contrast Agents
Article code: 801b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.